ArticleNeurourology and urodynamics2026
Long-Term Outcomes of Sacral Neuromodulation Explantation: A 12-Year Experience at a High-Volume Tertiary Center.
Article in Neurourology and urodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSacral neuromodulation (SNM) is a therapeutic option offered to patients with idiopathic overactive bladder (OAB) or non-obstructive urinary retention, as an alternative treatment for refractory medical management. It allows for electrical stimulation of inhibitory circuits that modulate the micturition reflex and improve lower urinary tract symptoms. Despite high efficacy and safety, explantation remains a challenge clinically as it is unknown which factors predict explantation. Herein, we sought to understand the factors influencing SNM explantation.
methodsWe conducted a long-term retrospective cohort study of 587 patients receiving SNM at one academic tertiary care center in Toronto, Ontario, performed by one surgeon.
resultsThe Kaplan-Meier analysis demonstrated explantation-free survival probabilities of 97% (95% CI 96%-99%) at 1 year, 92% (90%-95%) at 3 years, and 81% (77%-86%) at 5 years. We did not determine any variables independently associated with time nor risk of explantation. The most common indication for explantation was loss of efficacy (57.7%), followed by patient preference (16.7%) and pain (16.7%).
conclusionExplantation after SNM occurs in a minority of patients, and is largely attributable to a loss of sustained therapeutic efficacy over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.